Egfr Inhibition Marker
Egfr Inhibition Marker - Related Videos
00:46
Feedback Inhibition
0 Views •
2019
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell! Since enzymes help control the rate of reactions, their activity is regulated so that appropriate amounts of starting materials, intermediate metabolites, and products are maintained in the cell. Excessive build-up or depletion of...
09:38
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
0 Views •
Cited by 4 •
2017
An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.
08:12
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
0 Views •
Cited by 4 •
2020
The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR proteins.
01:30
Enzyme Inhibition
0 Views •
2025
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure. Competitive inhibitors occupy the active site of enzymes, making them unable to accommodate the substrate. However, sufficiently high...
02:29
Measuring Immune-Induced Inhibition of Seedling Growth
0 Views •
2025
This video demonstrates the seedling growth inhibition assay in the Arabidopsis thaliana plant. The impact of increased concentration of immune peptide elicitor on seedling growth is determined.
FAQs
Reduced EGFR phosphorylation provides a proximal molecular readout that the receptor is less active after inhibitor treatment. Because EGFR is a receptor tyrosine kinase, its phosphorylation reflects signaling activation rather than merely receptor presence. Measuring this change helps distinguish reduced receptor activity from simply detecting EGFR expression in neural cells, glial models, or brain-tumor systems.
Downstream MAPK and PI3K-AKT measurements show whether reduced receptor activity is transmitted through major signaling routes. EGFR phosphorylation may decrease without fully describing the pathway response, whereas downstream changes indicate how signaling output is altered. Using these markers together can clarify whether treatment affects signaling broadly and support comparisons of inhibitor responses across neural research models.
An inhibition marker reports reduced signaling activity, such as decreased EGFR phosphorylation or altered MAPK and PI3K-AKT signaling. An expression measurement instead indicates how much EGFR is present. This distinction matters because receptor abundance alone does not establish that an inhibitor has reduced EGFR activity, while phosphorylation and downstream pathway changes provide evidence of functional response.
A typical assessment compares molecular signaling in a model after exposure to an EGFR inhibitor, focusing on EGFR phosphorylation and, when relevant, MAPK or PI3K-AKT pathway changes. The same marker strategy can be applied to neural cells, glial models, or brain-tumor systems. The resulting measurements indicate whether treatment produced the expected molecular response.
These markers are applicable in neural cells, glial models, and brain tumors, allowing researchers to examine EGFR signaling in different nervous-system contexts. In neural cells and glia, the measurements can support studies of neurodevelopment and neural repair. In brain-tumor research, they help evaluate whether treatment changes a signaling system linked to tumor biology.
EGFR inhibition markers connect treatment exposure with molecular signaling changes in processes relevant to the nervous system. Researchers can use them to compare treatment responses, investigate how EGFR signaling contributes to neurodevelopment or neural repair, and examine drug activity in brain tumors. Their value lies in linking a measurable pathway response with disease or developmental research questions.